Answers are grounded in this paper and cite their sources.
Investigations reveal the safety and efficacy of 177Lu-DOTA-IBA therapy for managing bone metastases, suggesting a promising treatment option.
Objective: DOTA-ibandronic acid (DOTA-IBA) is a recently developed prodrug targeting bone metastases. Labeling with 68 Ga/ 177 Lu ( 68 Ga/ 177 Lu-DOTA-IBA) induces good curative effects and safety in these patients. However, there has been no evaluation of the safety and effectiveness of 177 Lu-DOTA-IBA in cases of multiple bone metastases. Here, the hematological toxicity and efficacy of 177 Lu-DOTA-IBA in cases of multiple bone metastases were investigated. Participants and Methods: Twenty-eight cases of multiple bone metastases were enrolled in the analysis. Following 177 Lu-DOTA-IBA treatment, blood biomarkers were monitored to evaluate the safety of treatment. Karnofsky Performance Status assessments (KPS), Visual Analogue Scale (VAS) pain scores, and 68 Ga-DOTA-IBA PET/CT follow-up were utilized for evaluation of the curative effect. Results: The 28 enrolled patients with multiple bone metastases had a median treatment cycle of 3. The baseline hematological parameters of 25 patients (89%) were abnormal. Post-treatment follow-up showed that blood counts remained essentially unchanged from baseline, with only one patient (4%) developed new grade 3 anemia. A 79% (22/28) rate of bone pain remission was observed and follow-up 68 Ga-DOTA-IBA PET/CT images showed that 15 cases (54%, 15/28) had partial remission. Conclusions: No serious adverse events were observed in patients with multiple bone metastases who received 177 Lu-DOTA-IBA. The therapeutic agent demonstrated promising efficacy, particularly for pain control and improved quality of life, suggesting that 177 Lu-DOTA-IBA is a safe, effective therapeutic option for this population.
No takes yet. Share an insight, caveat, or question.
Hua et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: